Boris Winterhoff

University of Minnesota

Full Professor(heuristic)

Ovarian cancer diagnosis and treatment · Reproductive Medicine

h-index53

i10-index82

Publications211

Citations20,343

Grants

No NSF/NIH grants on record.

Lab Funding Health

Find elsewhere

Institution / lab homepage Search on ResearchGate

In-Field Influence

0.0136

PageRank within Reproductive Medicine co-authorship network

Explore collaboration map

Admission Signals

New paper: Abstract CT260: Pembrolizumab and epigenetic modification with azacitidine reprogram the tumor microenvironment of platinum-resistant epithelial ovarian cancer: clinical and translational findings from a phase II study (Cancer Research)2026-04-17
New preprint: Tumor Cells Enriched for Interferon and Inflammatory Programs Pre-Exist in High Grade Serous Ovarian Cancer and are Proportionately Significantly Increased Post Chemotherapy2025-06-25

Data Freshness

Publications as of 2026-07-01
Grants as of 2026-06-30

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

ORCID: 0000-0002-1334-8650

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 18 of 18

Abstract CT260: Pembrolizumab and epigenetic modification with azacitidine reprogram the tumor microenvironment of platinum-resistant epithelial ovarian cancer: clinical and translational findings from a phase II study
Cancer Research · 2026-04-17
Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial
Communications Medicine · 2026-02-06
From intractable hiccups to optic neuritis: paraneoplastic neuromyelitis optica with leptomeningeal carcinomatosis in the setting of immature ovarian teratoma
Gynecologic Oncology Reports · 2025-11-16
Abstract B042: STAR (Stroma-Tumor AI Risk) Assessment: Association of AI-derived tumor-stroma proportion with patient survival provides added prognostic value beyond KELIM in epithelial ovarian cancer
Cancer Research · 2025-09-19
1074P Claudin- 6 (CLDN6) is a therapeutic target in ovarian cancer (OC): Emerging results from the CATALINA 1 (CAT1) study
Annals of Oncology · 2025-09-01 · 1 citations
1225TiP CATALINA-2/ENGOT-ov83: A phase II study of TORL-1-23 monotherapy in advanced platinum-resistant epithelial ovarian cancer expressing Claudin 6
Annals of Oncology · 2025-09-01 · 1 citations
A phase II study of pembrolizumab monotherapy in recurrent ovarian cancer of the immunoreactive subtype determined by NanoString PrOTYPE gene expression profiling
Gynecologic Oncology · 2025-09-01
Tumor Cells Enriched for Interferon and Inflammatory Programs Pre-Exist in High Grade Serous Ovarian Cancer and are Proportionately Significantly Increased Post ChemotherapyPreprint
bioRxiv (Cold Spring Harbor Laboratory) · 2025-06-25 · 1 citations
Abstract 1249: Chemotherapy enriches one of two pre-existing coordinated cellular programs characterized by inflammatory and stress pathways in high grade serous ovarian cancer
Cancer Research · 2025-04-21
Supplementary Data from ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in CancerPreprint
2025-04-03
Data from ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in CancerPreprint
2025-04-03
ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer
Cancer Research · 2025-01-13 · 7 citations
Investigating proteogenomic divergence in patient-derived xenograft models of ovarian cancer
Scientific Reports · 2025-01-04 · 3 citations
Artificial Intelligence-Assessed Tumor-Stroma Proportion Outperforms Kelim in Predicting Treatment Response and Outcomes in Epithelial Ovarian CancerPreprint
SSRN Electronic Journal · 2025-01-01
From Intractable Hiccups to Optic Neuritis: Paraneoplastic Neuromyelitis Optica in the Setting of Immature Ovarian TeratomaPreprint
SSRN Electronic Journal · 2025-01-01
ZNFX1 is a Novel Master Regulator in Epigenetically-induced Pathogen Mimicry and Inflammasome Signaling in CancerPreprint
bioRxiv (Cold Spring Harbor Laboratory) · 2024-10-21
PR031/#1199 Phase I, two-part, mutlicenter, first-in-human (FIH) study of TORL-1–23, a novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patients with advanced solid tumors
International Journal of Gynecological Cancer · 2024-10-01 · 1 citations
721MO Phase I, two-part, multicenter first-in-human (FIH) study of TORL-1-23: A novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patient with advanced solid tumors
Annals of Oncology · 2024-09-01 · 12 citations

Open author page on OpenAlex →